NexMed and Ångstrom Pharmaceuticals to Present Data on Å6 Drug at AACR
April 13 2010 - 11:00AM
Business Wire
NexMed, Inc. (Nasdaq: NEXM), a specialty CRO with a pipeline of
products based on the NexACT® technology, today announced that
Bio-Quant, its wholly-owned subsidiary, and Ångstrom
Pharmaceuticals, a privately-held pharmaceutical company, will
jointly present data at the 101st Annual Meeting of the American
Association for Cancer Research (AACR), in Washington, D.C. from
April 17-21, 2010. The poster presentation, entitled, “Å6 peptide
binds to CD44 and inhibits migration and metastasis of CD44+ cell
lines in in vitro and in vivo studies,” covers pre-clinical work
completed by Bio-Quant on Ångstrom’s lead product, Å6, currently in
Phase 2 development for ovarian cancer.
Bassam Damaj, Ph.D., President and Chief Executive Officer of
NexMed, and one of the presenters at AACR, stated, “We are pleased
to have supported Ångstrom in their target identification of the Å6
drug. Å6 has demonstrated activity in in vitro models of cell
migration, invasion and angiogenesis, as well as in breast,
prostate and brain tumor models. Similar activity was also seen in
animal models of ocular disease. The results support the efficacy
of Å6 across various cancer cells, which suggests that the drug is
addressing a fundamental pathway for proliferative and invasive
diseases.”
Malcolm Finlayson, Ph.D., President and Chief Executive Officer
of Ångstrom, noted, “The work done by NexMed’s Bio-Quant team on
behalf of Ångstrom is a testament to their expertise in the field
of oncology. We look forward to the results of the ongoing studies
on the mechanism of action of Å6.”
About Ångstrom Pharmaceuticals
and Å6
Based in San Diego, CA, Ångstrom is developing a new class of
drugs targeting CD44 for the treatment of diseases involving cell
migration, invasion, and metastasis. Results from a completed Phase
1a safety clinical trial on Å6 showed there were no systemic
drug-related adverse events in healthy volunteers. Ångstrom has
also successfully completed a Phase 1b clinical trial evaluating Å6
in women with advanced gynecologic cancer, and a Phase 2 clinical
trial evaluating Å6 in women with asymptomatic CA125 progression of
epithelial ovarian cancer after first-line chemotherapy. Treatments
were well tolerated and more than 40% of the patients dosed
continuously with Å6 experienced disease stabilization. For further
information, go to www.angstrominc.com.
About NexMed
NexMed is the largest specialty CRO based in San Diego, CA and
is one of the industry's most experienced CROs for in vitro and in
vivo pharmacology services and research models. The Company’s goal
is to generate revenues from the growth of its Discovery
Pre-clinical CRO business, while aggressively seeking to monetize
its proprietary NexACT drug delivery technology through
out-licensing agreements with pharmaceutical and biotechnology
companies, worldwide. At the same time, NexMed is actively pursuing
partnering opportunities for its NexACT-based treatments for
onychomycosis, psoriasis, sexual dysfunction and cancer. For
further information on NexMed and its subsidiaries, visit the
following websites: http://www.nexmed.com or
http://www.bio-quant.com.
Nexmed (MM) (NASDAQ:NEXM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nexmed (MM) (NASDAQ:NEXM)
Historical Stock Chart
From Sep 2023 to Sep 2024